ArticleBMC cancer2026
Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe use of venetoclax in combination with hypomethylating agents (HMAs) has become a standard treatment approach for both newly diagnosed and relapsed/refractory (R/R) AML patients who are ineligible for intensive chemotherapy. We aimed to share the real-life data of this combination therapy.
methodThis retrospective study included 38 patients with newly diagnosed or R/R AML who received at least one cycle of venetoclax-HMA combination therapy between July 2018 and August 2025. Response status, survival rates, and the incidence of hematological adverse events were analyzed.
resultsTwelve patients (31.6%) were treatment-naive, while the remaining 26 (68.4%) were R/R AML. The median age of all patients was 67, and 57.9% were male. 23.7% of the patients were in the poor-risk group. The overall response rate (ORR) was 73.7% in the entire cohort, and 83.3% and 69.2% in the first-line and R/R groups, respectively. No statistically significant difference in ORR was observed between the newly diagnosed and R/R groups (p = 0.453); however, given the small sample sizes - particularly in the newly diagnosed arm (n = 12) - this study was insufficiently powered to detect or exclude a clinically meaningful difference between groups. The restricted mean progression-free survival (RMST-PFS) was 18.35 months (95% CI 15.16-21.22), and the restricted mean overall survival (RMST-OS) was 21.12 months (95% CI 19.03-22.86). As adverse events, grade 3 or higher neutropenia was 39.5% and thrombocytopenia was 31.6%.
conclusionIn this single-center real-world experience, venetoclax-HMA combination therapy demonstrated response rates and a toxicity profile consistent with those reported in larger studies, supporting its feasibility in routine clinical practice for AML patients ineligible for intensive chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.